Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Main billing specialties: vascular surgery and interventional radiology.
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in the 45 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 55 | 5,650+1.5%/yr | +1.5%/yr | 2.61.7× | 32% | 8,010 in 2030+6%/yr |
| California | 42 | 4,550+3.4%/yr | +3.4%/yr | 1.40.9× | 29% | 6,830 in 2030+7%/yr |
| Texas | 30 | 4,117+1.6%/yr | +1.6%/yr | 1.91.3× | 17% | 6,020 in 2030+6.5%/yr |
| New York | 24 | 2,696−2.3%/yr | −2.3%/yr | 1.51.0× | 17% | 3,720 in 2030+5.5%/yr |
| Illinois | 28 | 2,235+1.2%/yr | +1.2%/yr | 1.61.1× | 18% | 3,030 in 2030+5.2%/yr |
| Pennsylvania | 14 | 1,998+1.6%/yr | +1.6%/yr | 1.51.0× | 9% | 2,310 in 2030+2.4%/yr |
| New Jersey | 25 | 1,782+1%/yr | +1%/yr | 1.71.1× | 28% | 1,690 in 2030−0.8%/yr |
| Michigan | 10 | 1,534−1.8%/yr | −1.8%/yr | 1.81.2× | 18% | 1,770 in 2030+2.4%/yr |
| Maryland | 20 | 1,433−0.5%/yr | −0.5%/yr | 1.61.1× | 45% | 1,430 in 20300%/yr |
| Ohio | 6 | 1,351−4.1%/yr | −4.1%/yr | 1.20.8× | 0% | 1,470 in 2030+1.4%/yr |
| Georgia | 9 | 1,269−2.2%/yr | −2.2%/yr | 1.51.0× | 9% | 1,580 in 2030+3.7%/yr |
| Indiana | 7 | 1,264+6.5%/yr | +6.5%/yr | 1.81.2× | 15% | 1,940 in 2030+7.4%/yr |
| Tennessee | 12 | 1,232−0.4%/yr | −0.4%/yr | 1.81.2× | 20% | 1,220 in 2030−0.1%/yr |
| Arizona | 11 | 1,180+4.1%/yr | +4.1%/yr | 1.61.1× | 19% | 1,490 in 2030+3.9%/yr |
| North Carolina | 4 | 1,069−0.8%/yr | −0.8%/yr | 1.10.7× | 0% | 1,460 in 2030+5.4%/yr |
| Virginia | 4 | 1,041−5.6%/yr | −5.6%/yr | 1.00.7× | 2% | 1,720 in 2030+8.7%/yr |
| South Carolina | 11 | 893+4.8%/yr | +4.8%/yr | 1.30.9× | 2% | 1,290 in 2030+6.4%/yr |
| Missouri | 8 | 855−5.5%/yr | −5.5%/yr | 1.40.9× | 0% | 790 in 2030−1.3%/yr |
| Massachusetts | 2 | 738−0.4%/yr | −0.4%/yr | 0.80.5× | 9% | 740 in 2030+0.1%/yr |
| Alabama | 7 | 675−4.4%/yr | −4.4%/yr | 1.61.0× | 12% | 640 in 2030−1%/yr |
| Colorado | 4 | 635+0.4%/yr | +0.4%/yr | 1.30.9× | 18% | 790 in 2030+3.6%/yr |
| Arkansas | 6 | 614+8.4%/yr | +8.4%/yr | 1.61.1× | 5% | 680 in 2030+1.8%/yr |
| Wisconsin | 1 | 601−4.2%/yr | −4.2%/yr | 1.10.7× | 5% | 1,010 in 2030+9.1%/yr |
| Oklahoma | 3 | 598+2.9%/yr | +2.9%/yr | 1.20.8× | 0% | 860 in 2030+6.2%/yr |
| Kentucky | 3 | 595+3.1%/yr | +3.1%/yr | 1.30.9× | 5% | 810 in 2030+5.2%/yr |
| Louisiana | 4 | 589−13%/yr | −13%/yr | 1.51.0× | 0% | 560 in 2030−0.8%/yr |
| Washington | 3 | 587+1.3%/yr | +1.3%/yr | 0.80.5× | 0% | 1,070 in 2030+11%/yr |
| Mississippi | 6 | 554+0.1%/yr | +0.1%/yr | 1.51.0× | 4% | 570 in 2030+0.6%/yr |
| Minnesota | 3 | 534−2.8%/yr | −2.8%/yr | 1.20.8× | 0% | 1,150 in 2030+14%/yr |
| Connecticut | 1 | 474−5.9%/yr | −5.9%/yr | 1.41.0× | 23% | 420 in 2030−1.9%/yr |
| Kansas | 2 | 454+4.3%/yr | +4.3%/yr | 1.10.8× | 0% | 920 in 2030+12%/yr |
| Nevada | 3 | 412−4.7%/yr | −4.7%/yr | 1.41.0× | 0% | 540 in 2030+4.7%/yr |
| Oregon | 2 | 343+2.3%/yr | +2.3%/yr | 0.80.5× | 0% | 370 in 2030+1.1%/yr |
| South Dakota | 6 | 318+3.2%/yr | +3.2%/yr | 2.51.6× | 0% | 220 in 2030−5.7%/yr |
| Iowa | 1 | 3090%/yr | 0%/yr | 0.70.5× | 0% | 490 in 2030+8.2%/yr |
| Nebraska | 1 | 272−1.9%/yr | −1.9%/yr | 1.10.7× | 0% | 220 in 2030−3.7%/yr |
| Idaho | 2 | 265+6.5%/yr | +6.5%/yr | 1.30.9× | 0% | 360 in 2030+5.1%/yr |
| Utah | 0 | 253+3.2%/yr | +3.2%/yr | 1.20.8× | 0% | 480 in 2030+11%/yr |
| West Virginia | 2 | 251−3%/yr | −3%/yr | 1.20.8× | 0% | 280 in 2030+1.6%/yr |
| Delaware | 2 | 241−1%/yr | −1%/yr | 1.40.9× | 44% | 850 in 2030+23%/yr |
| District of Columbia | 1 | 238−4.9%/yr | −4.9%/yr | 3.82.5× | 10% | 210 in 2030−1.8%/yr |
| New Mexico | 1 | 215+4.7%/yr | +4.7%/yr | 0.90.6× | 0% | 60 in 2030−18%/yr |
| Montana | 2 | 147+16%/yr | +16%/yr | 0.80.5× | 0% | 150 in 2030+0.1%/yr |
| New Hampshire | 0 | 145−3.6%/yr | −3.6%/yr | 0.60.4× | 0% | 220 in 2030+7.6%/yr |
| North Dakota | 1 | 126−1.2%/yr | −1.2%/yr | 1.30.8× | 0% | 260 in 2030+13%/yr |
Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 156 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 31 companies. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 27 |
| BD | 16 |
| Cook | 16 |
| Penumbra | 14 |
| Boston Scientific | 9 |
| Alembic | 7 |
| Imperative Care | 7 |
| Perfuze | 6 |
| Rapid Medical | 6 |
| Johnson & Johnson MedTech | 5 |
| Neuravi | 5 |
| Philips Image Guided Therapy | 5 |
Product codes: DTK (filter, intravascular, cardiovascular), NRY (catheter, thrombus retriever), QAN (stent, iliac vein). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 37% of the cases CMS names in Florida; 35 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Peripheral arterial intervention | 1,321 | 182,726−5.9%/yr | −5.9%/yr | 215,300 in 2030+2.8%/yr |
| Superficial venous ablation | 1,980 | 166,794−4.1%/yr | −4.1%/yr | 191,600 in 2030+2.3%/yr |
| Dialysis access | 1,721 | 161,268−13%/yr | −13%/yr | 158,700 in 2030−0.3%/yr |
| Carotid revascularization | 741 | 36,694−5%/yr | −5%/yr | 40,000 in 2030+1.5%/yr |
| Aortic endografts (EVAR/TEVAR) | 89 | 13,204−6.8%/yr | −6.8%/yr | 13,800 in 2030+0.7%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 17 companies reported engagement with surgeons in the covered states worth $11M in consulting, speaking, meals and travel tied to these products, about $29K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.